SCM
ORIC icon

Superstring Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Superstring Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$1.61M – 46
2024
Q4 		$1.61M Buy
+200,000
New +$1.84M 1.4% 20

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Superstring Capital Management's ORIC Position: Q2 2026 in Review

Superstring Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 252% in Q2 2026, buying an estimated $2.64M and bringing the position to 406,077 shares worth $4.4M. The position accounts for 2.78% of the portfolio, ranked #15.

Superstring Capital Management first reported a position in ORIC in Q3 2024 and has held it in 8 quarters since. The position peaked at $12.8M in Q4 2024. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Superstring Capital Management held 406,077 shares of Oric Pharmaceuticals worth $4.4M as of Q2 2026.
  • Superstring Capital Management bought 290,843 Oric Pharmaceuticals shares in Q2 2026, an estimated $2.64M.
  • Oric Pharmaceuticals made up 2.78% of Superstring Capital Management's portfolio in Q2 2026, its #15 holding.
  • Superstring Capital Management first reported a position in Oric Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Superstring Capital Management's Oric Pharmaceuticals position peaked at $12.8M in Q4 2024.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.